The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease

Brain

Volumn 123, Issue 3, 2000, Pages 585-590

  Schiefermeier, M ^a   Kollegger, H ^a   Madl, C ^a   Polli, C ^a   Oder, W ^a   Kuhn H J ^b   Berr, F ^b   Ferenci, P ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Apolipoprotein E; Clinical manifestations; H1069Q mutation; Wilson's disease

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ADOLESCENT; ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENOTYPE; HOMOZYGOTE; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROPROTECTION; ONSET AGE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHOOL CHILD; SYMPTOM; WILSON DISEASE;

EID: 0033975764     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.3.585     Document Type: Article

References (26)

1. Alberts MJ, Graffagnino C, McClenny C, DeLong D, Strittmatter W, Saunders AM, et al. ApoE genotype and survival from intracerebral haemorrhage [letter]. Lancet 1995; 346: 575.
2. Czlonkowska A, Rodo M, Gajda J, Ploos van Amstel HK, Juyn J, Houwen RH. Very high frequency of the His1069Gln mutation in Polish Wilson disease patients [letter]. J Neurol 1997; 244: 591-2.
3. de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. [Review]. Hum Mutat 1994; 4: 178-94.
4. Fukushima N, Yamamoto K, Ozaki I, Sakai T. Apolipoprotein A-1, E, C-III and LDL-receptor mRNA expression in liver diseases. [Review]. [Japanese]. Nippon Rinsho 1993; 51: 407-13.
5. Gollan JL, Gollan TJ. Wilson disease in 1998: genetic, diagnostic and therapeutic aspects. [Review]. J Hepatol 1998; 28 (Suppl 1): 28-36.
6. Gouras GK, Relkin NR, Sweeney D, Munoz DG, Mackenzie IR, Gandy S. Increased apolipoprotein E ε4 in epilepsy with senile plaques. Ann Neurol 1997; 41: 402-4.
7. Grimm G, Oder W, Prayer L, Ferenci P, Madl C. Evoked potentials in assessment and follow-up of patients with Wilson's disease. Lancet 1990; 336: 963-4.
8. Hayek T, Oiknine J, Brook JG, Aviram M. Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem Biophys Res Commun 1994; 201: 1567-74.
9. Houwen RH, Juyn J, Hoogenraad TU, Ploos van Amstel JK, Berger R. H714Q mutation in Wilson disease is associated with late, neurological presentation. J Med Genet 1995; 32: 480-2.
10. Jo DW, Leren TP, Yang ZY, Chung YH, Taylor JM, Paik YK. Characterization of an upstream regulatory element of the human apolipoprotein E gene, and purification of its binding protein from the human placenta. J Biochem (Tokyo) 1995; 117: 915-22.
11. Laskowitz DT, Sheng H, Bart RD, Joyner KA, Roses AD, Warner DS. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab 1997; 17: 753-8.
12. Maier-Dobersberger T, Ferenci P, Polli C, Balác P, Dienes HP, Kaserer K, et al. Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction. Ann Intern Med 1997; 127: 21-6.
13. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nature Genet 1996; 14: 55-61.
14. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro. Science 1994; 264: 850-2.
15. Oder W, Prayer L, Grimm G, Spatt J, Ferenci P, Kollegger H, et al. Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 1993; 43: 120-4.
16. Petrukhin K, Lutsenko S, Chernov I, Ross BM, Kaplan JH, Gilliam TC. Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. Hum Mol Genet 1994; 3: 1647-56.
17. Schmidt R, Schmidt H, Fazekas F, Schumacher M, Niederkorn K, Kapeller P, et al. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke 1997; 28: 951-6.
18. Shah AB, Chernov I, Zhang HT, Ross BM, Das K, Lutsenko S, et al. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet 1997; 61: 317-28.
19. Sheng H, Laskowitz DT, Bennett E, Schmechel DE, Bart RD, Saunders AM, et al. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab 1998; 18: 361-6.
20. Siest G, Pillot T, Régis-Bailly A, Leininger-Müller B, Steinmetz J, Galteau MM, et al. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. [Review]. Clin Chem 1995; 41: 1068-86.
21. Snipes GJ, McGuire CB, Norden JJ, Freeman JA. Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells. Proc Natl Acad Sci USA 1986; 83: 1130-4.
22. Steindl P, Ferenci P, Dienes HP, Grimm G, Pabinger I, Madl C, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113: 212-8.
23. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997; 350: 1069-71.
24. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: spectrum of mutations and their consequences. Nature Genet 1995; 9: 210-7.
25. Waldenstrom E, Lagerkvist A, Dahlman T, Westermark K, Landegren U. Efficient detection of mutations in Wilson disease by manifold sequencing. Genomics 1996; 37: 303-9.
26. Welsh-Bohmer KA, Gearing M, Saunders AM, Roses AD, Mirra S. Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease. Ann Neurol 1997; 42: 319-25.